Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
World game at war: why some European nations have threatened a World Cup boycott 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
DURHAM, N.C., May 02, 2018 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Wednesday, May 9, 2018 at 4:30 p.m. ET to discuss first quarter 2018 financial results and recent operational highlights. A question-and-answer session will follow Dova's remarks.
To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7691889 five to 10 minutes before the start of the call.
A live audio webcast of the call will also be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.
Contacts
Mark Hahn
Chief Financial Officer
(919) 338-7936
[email protected]@dova.com
Westwicke Partners
John Woolford
(443) 213-0506
[email protected]
